Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2018.01641
Full Text
Open PDFAbstract
Available in full text
Date
July 16, 2018
Authors
Publisher
Frontiers Media SA